Pfizer – Recall of Chantix® (varenicline)

Pfizer announced the escalation of the voluntary recall of Chantix (varenicline) tablets from the wholesale-level to the consumer-level due to the presence of a nitrosamine, N-nitroso-varenicline, above the Pfizer established acceptable daily intake (ADI) level. A total of twelve lots of Chantix tablets are being recalled. July 19, 2021

Pfizer – Chantix® (varenicline) shortage update

The FDA announced that in order to ensure patient access to Chantix (varenicline), certain manufacturers are allowed to temporarily distribute varenicline tablets containing N-nitroso-varenicline, a nitrosamine impurity. July 16, 2021